Literature DB >> 35638361

Proceedings of the Clinical Microbiology Open 2018 and 2019 - a Discussion about Emerging Trends, Challenges, and the Future of Clinical Microbiology.

Christopher D Doern1, Melissa B Miller2, Kevin Alby2, Michael A Bachman3, Stephen M Brecher4, Aida Casiano-Colon5, Marc Roger Couturier6, J Kristie Johnson7, James E Kirby8,9, Erin McElvania10, Duane W Newton11, Frederick S Nolte12, Preeti Pancholi13, Peggy McNult14, Vaishali Dharmarha14, Sherry Dunbar15.   

Abstract

Clinical Microbiology Open (CMO), a meeting supported by the American Society for Microbiology's Clinical and Public Health Microbiology Committee (CPHMC) and Corporate Council, provides a unique interactive platform for leaders from diagnostic microbiology laboratories, industry, and federal agencies to discuss the current and future state of the clinical microbiology laboratory. The purpose is to leverage the group's diverse views and expertise to address critical challenges, and discuss potential collaborative opportunities for diagnostic microbiology, through the utilization of varied resources. The first and second CMO meetings were held in 2018 and 2019, respectively. Discussions were focused on the diagnostic potential of innovative technologies and laboratory diagnostic stewardship, including expansion of next-generation sequencing into clinical diagnostics, improvement and advancement of molecular diagnostics, emerging diagnostics, including rapid antimicrobial susceptibility and point of care testing (POCT), harnessing big data through artificial intelligence, and staffing in the clinical microbiology laboratory. Shortly after CMO 2019, the coronavirus disease 2019 (COVID-19) pandemic further highlighted the need for the diagnostic microbiology community to work together to utilize and expand on resources to respond to the pandemic. The issues, challenges, and potential collaborative efforts discussed during the past two CMO meetings proved critical in addressing the COVID-19 response by diagnostic laboratories, industry partners, and federal organizations. Planning for a third CMO (CMO 2022) is underway and will transition from a discussion-based meeting to an action-based meeting. The primary focus will be to reflect on the lessons learned from the COVID-19 pandemic and better prepare for future pandemics.

Entities:  

Keywords:  COVID; next-generation sequencing; pandemic; point of care testing; staffing; stewardship; utilization

Mesh:

Year:  2022        PMID: 35638361      PMCID: PMC9297828          DOI: 10.1128/jcm.00092-22

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   11.677


  25 in total

Review 1.  Assuring the Quality of Next-Generation Sequencing in Clinical Microbiology and Public Health Laboratories.

Authors:  Amy S Gargis; Lisa Kalman; Ira M Lubin
Journal:  J Clin Microbiol       Date:  2016-08-10       Impact factor: 5.948

2.  Our Pathogens Are Not Standing Still and Neither Can We.

Authors:  James E Kirby
Journal:  Clin Lab Med       Date:  2019-09       Impact factor: 1.935

3.  Intuitive and inspirational, or inductive and incremental?

Authors:  J P Kassirer; R I Kopelman
Journal:  Hosp Pract (Off Ed)       Date:  1988-09-15

Review 4.  Performance and Application of 16S rRNA Gene Cycle Sequencing for Routine Identification of Bacteria in the Clinical Microbiology Laboratory.

Authors:  Deirdre L Church; Lorenzo Cerutti; Antoine Gürtler; Thomas Griener; Adrian Zelazny; Stefan Emler
Journal:  Clin Microbiol Rev       Date:  2020-09-09       Impact factor: 26.132

5.  Detection of Intestinal Protozoa in Trichrome-Stained Stool Specimens by Use of a Deep Convolutional Neural Network.

Authors:  Orly Ardon; Marc Roger Couturier; Blaine A Mathison; Jessica L Kohan; John F Walker; Richard Boyd Smith
Journal:  J Clin Microbiol       Date:  2020-05-26       Impact factor: 5.948

6.  WGS to predict antibiotic MICs for Neisseria gonorrhoeae.

Authors:  David W Eyre; Dilrini De Silva; Kevin Cole; Joanna Peters; Michelle J Cole; Yonatan H Grad; Walter Demczuk; Irene Martin; Michael R Mulvey; Derrick W Crook; A Sarah Walker; Tim E A Peto; John Paul
Journal:  J Antimicrob Chemother       Date:  2017-07-01       Impact factor: 5.790

7.  Recognition of Diagnostic Gaps for Laboratory Diagnosis of Fungal Diseases: Expert Opinion from the Fungal Diagnostics Laboratories Consortium (FDLC).

Authors:  Sean X Zhang; N Esther Babady; Kimberly E Hanson; Amanda T Harrington; Paige M K Larkin; Sixto M Leal; Paul M Luethy; Isabella W Martin; Preeti Pancholi; Gary W Procop; Stefan Riedel; Seyedmojtaba Seyedmousavi; Kaede V Sullivan; Thomas J Walsh; Shawn R Lockhart
Journal:  J Clin Microbiol       Date:  2021-06-18       Impact factor: 5.948

Review 8.  The landscape of inappropriate laboratory testing: a 15-year meta-analysis.

Authors:  Ming Zhi; Eric L Ding; Jesse Theisen-Toupal; Julia Whelan; Ramy Arnaout
Journal:  PLoS One       Date:  2013-11-15       Impact factor: 3.240

9.  Rapid testing and treatment for sexually transmitted infections improve patient care and yield public health benefits.

Authors:  Gary G Whitlock; Daniel C Gibbons; Nick Longford; Michael J Harvey; Alan McOwan; Elisabeth J Adams
Journal:  Int J STD AIDS       Date:  2017-10-23       Impact factor: 1.359

10.  Species Identification and Antibiotic Resistance Prediction by Analysis of Whole-Genome Sequence Data by Use of ARESdb: an Analysis of Isolates from the Unyvero Lower Respiratory Tract Infection Trial.

Authors:  Ines Ferreira; Stephan Beisken; Lukas Lueftinger; Thomas Weinmaier; Matthias Klein; Johannes Bacher; Robin Patel; Arndt von Haeseler; Andreas E Posch
Journal:  J Clin Microbiol       Date:  2020-06-24       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.